Publications by authors named "S A Shoaf"
Article Synopsis
- A Phase 1, open-label pharmacokinetic trial was conducted to compare the timing accuracy of participant-collected versus staff-collected data for the drug centanafadine.
- Healthy adults aged 18-55 received the drug and had their pharmacokinetic samples and safety assessments collected at different visits, with incremental levels of participant involvement over the visits.
- The study found that at least 75% of participants successfully collected blood microsamples on time, and there were no treatment-related adverse events, supporting the feasibility of at-home data collection for pharmacokinetics.
Key Points: In a analysis, short-term reduction in spot urine osmolality (Uosm) was associated with decreased kidney volume growth in autosomal dominant polycystic kidney disease for both tolvaptan and instruction to increase hydration alone. For the same spot Uosm reduction, however, the kidney volume benefit was greater with tolvaptan, possibly because of greater cumulative 24-hour Uosm suppression by tolvaptan.
Background: In addition to decreasing water excretion and increasing urinary concentration, the antidiuretic hormone vasopressin plays a role in the pathophysiology of autosomal dominant polycystic kidney disease.
Background: Tolvaptan slows expansion of kidney volume and kidney function decline in adults with autosomal dominant polycystic kidney disease (ADPKD). Progression during childhood could be treated before irreversible kidney damage occurs, but trial data are lacking. We evaluated the safety and efficacy of tolvaptan in children/adolescents with ADPKD.
View Article and Find Full Text PDFBackground: Centanafadine is an inhibitor of reuptake transporters for norepinephrine (NET), dopamine (DAT) and serotonin (SERT).
Aims: This phase 1, adaptive-design positron emission tomography study investigated the occupancy time course of NET, DAT, and SERT and the relationship to centanafadine plasma concentrations.
Methods: Healthy adult males received centanafadine sustained-release 400 mg/day for 4 days ( = 6) or 800 mg in a single day ( = 4).